ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. “I want to offer my gratitude, and my congratulations to Peter Cuneo on his retirement from the electro ...

Midea MASTER Series Refrigerators Midea MASTER Series Refrigerators BERLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- At Midea, we're committed to constantly innovating, elevating the performance of home appliances that enhance our everyday lives to be more efficient, effective and simply better. Therefore, we’re proud to showcase the latest in our lineup of home refrigerators across four product series here at IFA, with models featuring cutting-edge technologies including AI-powered cooling optimization and f ...

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS). The collaboration co ...

STUART, Fla., Sept. 5, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced strategic leadership appointments designed to advance AI utilization and accelerate company growth. Dustin Plantholt, formerly our Chief Growth Officer, has been appointed Chief Artificial Intelligence & Marketing Officer, where he will spearhead the company's AI strategy and lead enterprise-wide marketing initiatives. In addition, Zain Hasan has joined ...

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. “This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “We began building a differentiated preclinical port ...

Vancouver, B.C. , Sept. 05, 2025 (GLOBE NEWSWIRE) -- NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) a digital asset and fintech platform bridging traditional capital markets with Web3 infrastructure, is pleased to announce the appointment of Mark Creaser, CEO of DSV Fund and a recognized leader in the Bittensor ecosystem, as an advisor. Matthew Priebe, NextGen’s CEO, commented: “Mark brings extensive expertise and network reach in the rapidly growing decentrali ...

VANCOUVER, BC, Sept. 5, 2025 /PRNewswire/ - Aris Mining Corporation (Aris Mining or the Company) (TSX: ARIS) (NYSE-A: ARMN) reports strong progress with the ramp-up at its Segovia Operations following successful commissioning of a second mill in June 2025. The expanded processing capacity has already delivered a substantial increase in mill throughput and gold production. Key highlights: Figure 1 – Segovia Operations - tonnes milled & processed grade (CNW Group/Aris Mining Corporation) Figure 1 – Segovia Op ...

Core Insights - The venture capital firm Solaire Partners will manage a KRW 40 billion (~USD $28 million) fund backed by Korea's three leading IPTV operators to finance 3-4 major films annually [2][4] - The fund aims to revitalize the IPTV VOD market, which has been challenged by the growth of OTT platforms, and to create a sustainable ecosystem for Korea's video content industry [3][4] Fund Highlights - The 'Solaire IPTV Video Investment Fund' focuses on securing high-quality content optimized for IPTV platforms and accelerating the delivery of new releases to viewers [4] - The IPTV market has seen a significant revenue decline in paid VOD, particularly in films, dropping from the second most popular viewing method in 2018 to fourth place in 2023 [4] Investment Strategy - Solaire Partners plans to leverage over 13 years of film industry data for quantitative analysis and insights from a team with over 100 years of collective experience [5] - The firm has a portfolio that includes successful films such as 'Parasite' and '12.12: The Day' [5][10] Strategic Vision - The fund management appointment enhances K Wave Media's value chain in content production, investment, and marketing following its acquisition of AI-powered digital content company Rabbit Walk [6] - The initiative aims to create a virtuous cycle where platforms and content producers thrive together, enhancing viewer satisfaction [7] Company Overview - K Wave Media (KWM) is focused on creating, distributing, and monetizing high-quality content across multiple platforms and has been pursuing strategic growth initiatives since going public in 2025 [8][9] - Solaire Partners is recognized for its data-driven investment approach and has established itself as a trusted partner in Korea's entertainment industry [10]

Group 1 - Jyske Realkredit A/S will list a new Covered Bond (SDO) on 10 February 2025, with final terms attached to the announcement [1] - The full prospectus for the bonds includes the final terms and the previously disclosed base prospectus dated June 27, 2025 [2] - The base prospectus is available on Jyske Realkredit's official website [2]

Core Insights - The article discusses the promising initial results from the Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, highlighting significant increases in α-Gal A activity among patients [1][4][3] Company Overview - uniQure N.V. is a gene therapy company focused on developing transformative therapies for severe medical conditions, including Fabry disease [1][10] - The company has previously achieved a milestone with its gene therapy for hemophilia B, showcasing its commitment to advancing genomic medicine [10] Clinical Trial Details - The Phase I/IIa trial of AMT-191 includes multiple cohorts, with the first cohort (Cohort A) showing α-Gal A activity increases of 27- to 208-fold above normal levels [3][4] - All patients in the first cohort discontinued enzyme replacement therapy (ERT) and maintained stable plasma lyso-Gb3 levels [3][4] - A second cohort (Cohort B) has been enrolled with a lower dose, and no serious adverse events (SAEs) have been reported to date [5] Safety and Efficacy - Preliminary data indicate that AMT-191 has a manageable safety profile, with some SAEs observed that were unrelated to the treatment [4][5] - The trial aims to explore the safety, tolerability, and early efficacy of AMT-191, with updated results expected in the first half of 2026 [1][6] Disease Context - Fabry disease is a genetic disorder caused by α-Gal A enzyme deficiency, leading to harmful substrate accumulation affecting various organs [2][9] - The current standard treatment involves bi-weekly ERT, which has limitations in effectiveness [9] Regulatory Status - AMT-191 has received Orphan Drug and Fast Track designations from the U.S. FDA, indicating its potential significance in treating Fabry disease [7]